Claims 22 and 24-30 (*renumbered as claims 22 and 26-32*) were rejected under 35 U.S.C. §112(1). The claims have been amended to the claim scope which the office action states is an enabling claim scope. Hence the rejection should be withdrawn.

Claims 22 and 24-30 (*renumbered as claims 22 and 26-32*) were rejected under 35 U.S.C. §112(2). The claims have been amended to overcome the rejection. Hence the rejection should be withdrawn. Support for the amendment "by lowering the level of a gonadotrophin secretion" can be found at at least page 24, lines 25-29 of the specification.

Claims 31-32 are hereby cancelled without prejudice to further prosecution at a later date.

All issues raised by the Office Action have been addressed. Reexamination, reconsideration and allowance of claims 22 and 26-30 is requested.

Respectfully submitted,

Stephen Donovan
Registration Number 33,433

Date March 9, 2004

Stephen Donovan
Allergan, Inc., Legal Department
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714 246 4026
Fax: 714 246 4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Response to Office Action and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date **March 9, 2004** in an envelope as "Express Mail Post Office to Addressee" Mail Label number **EV193720889US** addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Bartholomew
Name of person mailing paper
Date: March 9, 2004

Signature of person signing

MARKED UP VERSION OF THE CLAIMS

1-21 (previously cancelled)

22. (currently amended) A method for treating a gonadotrophin related illness in a mammal, said method comprises the step of administering to the mammal a therapeutically effective amount of an agent, the agent comprises:

(a) a LH_N which comprises (i) light chain component comprising a light chain L, of a botulinum toxin, a butyricum toxin, or a tetani toxin and ~~,~~

(ii) a translocation component comprising a heavy chain H_N, of a botulinum toxin, a butyricum toxin, or a tetani toxin~~,~~ ; and

(b) a targeting component which comprises a gonadotrophin-releasing hormone (GnRH) or a GnRH analog, wherein the LH_N is covalently coupled to the GnRH or a GnRH analog , and wherein the targeting component selectively binds to a GnRH receptor wherein the gonadotrophin related illness is selected from the group consisting of breast cancer, prostate cancer, pancreatic cancer, and endometrial cancer,

thereby treating a gonadotrophin related illness by lowering the level of a gonadotrophin secretion.

23. (previously cancelled)

24-25 (previously cancelled)

26~~4~~. (previously added) The agent according to claim 22 wherein the light chain component decreases the release of a hormone from a cell.

27~~5~~. (previously added) The agent according to claim 22 wherein the light chain component comprises a light chain of a botulinum toxin type A, B, C_1, D, E, F, or G.

28~~6~~. (previously added) The agent according to claim 22 wherein the light chain component comprises a light chain of a botulinum toxin type A.

29~~7~~. (previously added) The agent according to claim 22 wherein the translocation component comprises a heavy chain of a botulinum toxin type A, B, C_1, D, E, F, or G.

30~~28~~. (previously added) The agent according to claim 22 wherein the translocation component comprises a heavy chain of a botulinum toxin type A.

31-32~~29-30~~ (cancelled)